Date: 2014-06-30
Type of information: Licensing agreement
Compound: E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,10-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione)]
Company: Boston Strategics Corporation, now Strategia Therapeutics (USA - MA) Eisai (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: kinase inhibitor/MEK inhibitor. E6201 is a synthetic, fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase kinase 1 (MEKK-1) with potential antipsoriatic and antineoplastic activities. MEK-1/MEKK-1 inhibitor E6201 specifically binds to and inhibits the activities of MEK-1 and MEKK-1, which may result in the inhibition of tumor cell proliferation. MEK-1 and MEKK-1 are key components in the RAS/RAF/MEK/MAPK signaling pathway, which regulates cell proliferation and is frequently activated in human cancers.
Disease: FLT3 mutated acute myeloid leukemia (AML) and other oncology indications
Details: * On June 30, 2014, Boston Strategics Corporation, an integrated clinical-stage drug research and development (R&D) company, announced that it has entered into an exclusive licensing and development agreement with Eisai, for E6201. Building on a strong scientific rationale supported by recent preclinical data, BSC will undertake a clinical Proof of Concept (PoC) trial in the high unmet need FLT3 mutated AML patients. Under this agreement with Eisai, BSC has worldwide rights to develop and commercialize E6201 for all Oncology indications.
Financial terms:
Latest news:
